February 18th 2025
Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.
February 11th 2025
Diabetes Dialogue: What to Know about the iLet Bionic Pancreas
May 26th 2023As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
Hour-Long Endoscopic Procedure Could Eliminate Need for Insulin in Type 2 Diabetes
May 4th 2023New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.
Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D
May 3rd 2023In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
Clinical Data on Finerenone in Diabetic Kidney Disease
April 27th 2023Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Tirzepatide Achieves Mean Weight Loss of 15.7% in SURMOUNT-2 Trial
April 27th 2023Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.
Omnipod GO Receives FDA Clearance for People with Type 2 Diabetes
April 25th 2023Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.
Healthy Beverage Choices May Lower Mortality Risk in Adults with Diabetes
April 20th 2023An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.
Diabetes Dialogue: News on Abbott Readers & CMS Expansion of CGM Availability
April 19th 2023Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
Study: Insulin Shelf Life Could Be 4 Times Longer than Previously Reported
April 12th 2023A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.